Wei‐Chen Lee
Impact in
-
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Diabetes Treatment and Management
- Oncology top 1%
- Global Cancer Incidence and Screening
Papers in
-
- Insurance, Mortality, Demography, Risk Management 7
- Co-authors
- Miin‐Fu Chen (2 shared papers)Hani Serag (11 shared papers)Ciro Valent Sumaya (2 shared papers)Long-Bin Jeng (3 shared papers)Maryam Tabrizi (4 shared papers)Chun‐Nan Yeh (1 shared paper)Marcia G. Ory (2 shared papers)Mukaila A. Raji (7 shared papers)
- Journals
- The Lancet (15 papers)The Lancet Public Health (8 papers)The Lancet Infectious Diseases (6 papers)Eye (4 papers)The Lancet Global Health (4 papers)
- Partner nations
- United StatesTaiwanIran
In The Last Decade
Wei‐Chen Lee
98 papers receiving 17.2k citations
Wei‐Chen Lee's Hit Papers
Peers
Comparison fields: 5 of 198
- Endocrinology, Diabetes and Metabolism 1.6k
- Oncology 1.9k
- Pharmacology 988
- Epidemiology 1.9k
- Health Information Management 526
Countries citing papers authored by Wei‐Chen Lee
This map shows the geographic impact of Wei‐Chen Lee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wei‐Chen Lee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wei‐Chen Lee more than expected).
Fields of papers citing papers by Wei‐Chen Lee
This network shows the impact of papers produced by Wei‐Chen Lee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wei‐Chen Lee. The network helps show where Wei‐Chen Lee may publish in the future.
Co-authors
The 25 scholars most cited alongside Wei‐Chen Lee, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 112 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 Hit paper breakdown → | 2024 | 3041 |
| 2 | Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021 Hit paper breakdown → | 2023 | 2997 |
| 3 | Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 Hit paper breakdown → | 2024 | 1712 |
| 4 | Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019 Hit paper breakdown → | 2021 | 1461 |
| 5 | Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 Hit paper breakdown → | 2024 | 1152 |
| 6 | Global, regional, and national burden of low back pain, 1990–2020, its attributable risk factors, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021 Hit paper breakdown → | 2023 | 970 |
| 7 | Global Burden of Cardiovascular Diseases and Risks, 1990-2022 Hit paper breakdown → | 2023 | 948 |
| 8 | Global, regional, and national burden of stroke and its risk factors, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 Hit paper breakdown → | 2024 | 702 |
| 9 | The global burden of cancer attributable to risk factors, 2010–19: a systematic analysis for the Global Burden of Disease Study 2019 Hit paper breakdown → | 2022 | 687 |
| 10 | Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950–2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021 Hit paper breakdown → | 2024 | 675 |
| 11 | Global, regional, and national prevalence of adult overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021 Hit paper breakdown → | 2025 | 463 |
| 12 | Population-level risks of alcohol consumption by amount, geography, age, sex, and year: a systematic analysis for the Global Burden of Disease Study 2020 Hit paper breakdown → | 2022 | 394 |
| 13 | Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023 Hit paper breakdown → | 2025 | 210 |
| 14 | 2021 | 200 | |
| 15 | Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021 Hit paper breakdown → | 2025 | 191 |
| 16 | National-level and state-level prevalence of overweight and obesity among children, adolescents, and adults in the USA, 1990–2021, and forecasts up to 2050 Hit paper breakdown → | 2024 | 176 |
| 17 | Assessing performance of the Healthcare Access and Quality Index, overall and by select age groups, for 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019 Hit paper breakdown → | 2022 | 171 |
| 18 | Global investments in pandemic preparedness and COVID-19: development assistance and domestic spending on health between 1990 and 2026 Hit paper breakdown → | 2023 | 159 |
| 19 | Global, regional, and national incidence of six major immune-mediated inflammatory diseases: findings from the global burden of disease study 2019 Hit paper breakdown → | 2023 | 101 |
| 20 | 2021 | 100 |
About Wei‐Chen Lee
Wei‐Chen Lee is a scholar working on General Health Professions, Demography, Epidemiology, Public Health, Environmental and Occupational Health and Health Information Management, having authored 112 papers that have together received 17.8k indexed citations. Recurring topics across this work include Insurance, Mortality, Demography, Risk Management (7 papers), Ophthalmology and Visual Impairment Studies (5 papers), Global Cancer Incidence and Screening (4 papers), Hepatocellular Carcinoma Treatment and Prognosis (4 papers), Opioid Use Disorder Treatment (4 papers), Global Health and Epidemiology (4 papers), Healthcare Systems and Reforms (3 papers) and Nursing care and research (3 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (1.6k citations), Oncology (1.9k citations), Pharmacology (988 citations), Epidemiology (1.9k citations) and Health Information Management (526 citations). Wei‐Chen Lee has collaborated with scholars based in United States, Taiwan and Iran. Frequent co-authors include Miin‐Fu Chen, Hani Serag, Ciro Valent Sumaya, Long-Bin Jeng, Maryam Tabrizi, Chun‐Nan Yeh, Marcia G. Ory, Mukaila A. Raji, Yong‐Fang Kuo and Shiguang Qian. Their work appears in journals such as The Lancet, The Lancet Public Health, The Lancet Infectious Diseases, Eye and The Lancet Global Health.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.